Extended Data Fig. 10: Characteristics of RET fusion-driven histiocytosis and response to selpercatinib.
From: Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
(a) Protein diagram of NCOA4-RET fusion identified in a cutaneous xanthogranuoma patient. Photographs of NCOA4-RET JXG skin lesions pre- and 12-weeks post selpercatinib on back (b), scrotum (c), and neck (d). (e) Number of Ba/F3 cells expressing an empty vector or the NCOA4-RET fusion following IL-3 withdrawal (mean of n = 3 independent biological experiments ± standard deviation). Calculation of p-values performed using two-way ANOVA; ****p < 0.0001. Representative western blotting (f) and phospho-protein flow cytometric analysis (g) of phospho-MEK1/2 and phosho-ERK1/2 in the cells from (e). Experiments performed in three independent biological experiments with similar results.
